Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic

NCT ID: NCT04387292

Last Updated: 2026-01-06

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 34 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-09-07
• Study Completion Date: 2021-05-15

Brief Summary

Ophthalmologic damages secondary to COVID-19 coronavirus infection are little described. The ocular involvement is probably multiple, ranging from pathologies of the anterior segment such as conjunctivitis and anterior uveitis to disorders that threaten vision such as retinitis or optic neuropathy. On the other hand, in addition to this impairment, when patients are hospitalized for acute respiratory failure, complications related to possible resuscitation, medication prescriptions, positioning and oxygenation.

COVID-19 itself, has several components:

• An apoptotic action of the viral attack which will generate cellular destruction, whether pulmonary, cardiac or renal or maybe ocular
• A secondary autoimmune action with the development of major vascular inflammation, possibly reaching the retinal, choroidal, and optic nerve vessels. A secondary "hyper" inflammatory syndrome with flashing hypercytokinemia and multi-organ decompensation is described in 3,7% to 4 ,3% of severe cases.
• A thromboembolic action

Detailed Description

Upon discharge from hospital for COVID-19 infection (or during a telephone call for patients already discharged at the start of the study), patients will be informed of the study. An ophthalmology appointment will be given to them between 4 and 6 months after their discharge.

During the ophthalmology appointment, the patient's clinical data will be collected during an interview (medical and treatment history, blood group). The patient will benefit from a full ophthalmological examination.

Conditions

COVID19; Ophthalmopathy

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: OTHER
• Blinding Strategy: NONE

Study Groups

Ophthalmologic exam

Group Type: EXPERIMENTAL

Ophthalmologic exam

Intervention Type: PROCEDURE

• Visual acuity (ETDRS exam)
• Slit lamp examination : fluorescein test, Oxford score, break up time, Schirmer II test
• Lipiview
• Eye pressure measurement (air tonometer)
• Wide field retinophotography
• Multicolor and auto-fluorescence retinophotography
• Indocyanine green retinal angiography
• Optical coherence tomography (OCT) B posterior pole scan
• OCT Angiography (OCT-A) of the optic nerve and posterior pole
• Adaptive optics
• Visual field (Humphrey)

Interventions

Ophthalmologic exam

• Visual acuity (ETDRS exam)
• Slit lamp examination : fluorescein test, Oxford score, break up time, Schirmer II test
• Lipiview
• Eye pressure measurement (air tonometer)
• Wide field retinophotography
• Multicolor and auto-fluorescence retinophotography
• Indocyanine green retinal angiography
• Optical coherence tomography (OCT) B posterior pole scan
• OCT Angiography (OCT-A) of the optic nerve and posterior pole
• Adaptive optics
• Visual field (Humphrey)

Intervention Type: PROCEDURE

Eligibility Criteria

Inclusion Criteria

• Patients having been hospitalized for a confirmed COVID-19 infection (CT-scanner or PCR- Polymerase chain reaction)

Exclusion Criteria

• Pregnant or breastfeeding woman

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Fondation Ophtalmologique Adolphe de Rothschild

NETWORK

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Martine MAUGET FAYSSE, MD

Role: PRINCIPAL_INVESTIGATOR

Fondation A. de Rothschild

Locations

Fondation A de Rothschild

Paris, France, France

Countries

France

References

Abdelmassih Y, Azar G, Bonnin S, Scemama Timsit C, Vasseur V, Spaide RF, Behar-Cohen F, Mauget-Faysse M. COVID-19 Associated Choroidopathy. J Clin Med. 2021 Oct 13;10(20):4686. doi: 10.3390/jcm10204686.

Reference Type: RESULT

PMID: 34682810 (View on PubMed)

Other Identifiers

MMT_2020_12

Identifier Type: -

Identifier Source: org_study_id